Literature DB >> 8988262

Increased serum interleukin-1-receptor-antagonist concentrations in major depression.

M Maes1, E Vandoolaeghe, R Ranjan, E Bosmans, R Bergmans, R Desnyder.   

Abstract

Recently, it has been shown that major depression may be accompanied by an increased production of interleukin-1 beta (IL-1 beta), an acute phase (AP) response and simultaneous signs of activation and suppression of cell-mediated immunity. The interleukin-1-receptor antagonist (IL-1-rA) is released in vivo during an AP response and serum levels are increased in many immune disorders. The release of IL-1-rA may limit the pro-inflammatory effects of IL-1. This study has been carried out to examine serum IL-1-Ra in 68 depressed subjects (21 minor, 25 simple major and 22 melancholic subjects) vs. 22 normal controls. Depressed subjects showed significantly higher serum IL-1-rA concentrations than healthy controls. 29% of all depressed subjects had serum IL-1-rA levels higher than the mean value +2 standard deviations of normal controls; 44% depressed subjects had IL-1-rA values greater than 0.215 ng/ml with a specificity of 90%. In depressed subjects, there was a significant and positive relationship between serum IL-1-rA and severity of illness. In depression, there were no significant relationships between serum IL-1-rA concentrations and indicants of hypothalamic-pituitary-adrenal (HPA)-axis activity, such as 24-h urinary cortisol and postdexamethasone cortisol values. Women had significantly higher serum IL-1-rA levels than men. The findings support the thesis that depression is accompanied by an immune-inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8988262     DOI: 10.1016/0165-0327(95)00049-6

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  25 in total

1.  Neurohormonal and inflammatory hyper-responsiveness to acute mental stress in depression.

Authors:  Ali A Weinstein; Patricia A Deuster; Jennifer L Francis; Robert W Bonsall; Russell P Tracy; Willem J Kop
Journal:  Biol Psychol       Date:  2010-01-29       Impact factor: 3.251

2.  Is exogenous administration of IL-1ra (anakinra) likely to induce severe depression?

Authors:  Annie Pierre Jonville-Bera; Jean-Louis Guilmot; Gilles Aspe; Elisabeth Autret-Leca; Julie Magnant
Journal:  Eur J Clin Pharmacol       Date:  2010-10-13       Impact factor: 2.953

3.  Neuro-oncology family caregivers are at risk for systemic inflammation.

Authors:  Paula R Sherwood; Thomas J Price; Jason Weimer; Dianxu Ren; Heidi S Donovan; Charles W Given; Barbara A Given; Richard Schulz; Jennifer Prince; Catherine Bender; Florien W Boele; Anna L Marsland
Journal:  J Neurooncol       Date:  2016-02-23       Impact factor: 4.130

4.  Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder.

Authors:  Jonathan Savitz; Wayne C Drevets; Brent E Wurfel; Bart N Ford; Patrick S F Bellgowan; Teresa A Victor; Jerzy Bodurka; T Kent Teague; Robert Dantzer
Journal:  Brain Behav Immun       Date:  2015-02-14       Impact factor: 7.217

5.  Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study.

Authors:  D Gimeno; M Kivimäki; E J Brunner; M Elovainio; R De Vogli; A Steptoe; M Kumari; G D O Lowe; A Rumley; M G Marmot; J E Ferrie
Journal:  Psychol Med       Date:  2008-06-04       Impact factor: 7.723

Review 6.  Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience.

Authors:  Caroline Ménard; Madeline L Pfau; Georgia E Hodes; Scott J Russo
Journal:  Neuropsychopharmacology       Date:  2016-06-13       Impact factor: 7.853

7.  Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI study.

Authors:  Yuri Milaneschi; Anna Maria Corsi; Brenda W Penninx; Stefania Bandinelli; Jack M Guralnik; Luigi Ferrucci
Journal:  Biol Psychiatry       Date:  2008-12-25       Impact factor: 13.382

Review 8.  Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications.

Authors:  Travis O Bruce
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

Review 9.  Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment.

Authors:  Alex D H Brown; David A Barton; Gavin W Lambert
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Elevated peripheral inflammation is associated with attenuated striatal reward anticipation in major depressive disorder.

Authors:  Kaiping Burrows; Jennifer L Stewart; Rayus Kuplicki; Leandra Figueroa-Hall; Philip A Spechler; Haixia Zheng; Salvador M Guinjoan; Jonathan B Savitz; T Kent Teague; Martin P Paulus
Journal:  Brain Behav Immun       Date:  2021-01-26       Impact factor: 19.227

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.